Floatz logo

FLUVOXAMINE

Advanced Solid Tumors, Excluding Breast Cancer

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1412 Active assets in the Advanced Solid Tumors, Excluding Breast Cancer cohort.

View all 50

Same molecule, other indications

FLUVOXAMINE is also rated in:

depressive disorderDormant
B
Indicative ·
62 / 100
View asset →
schizophreniaDormant
B
Indicative ·
60 / 100
View asset →
physiological malfunction arising from mental factorDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →